How can Facebook…burst the filter bubble? https://www.NewScientist.com/article/2113246-how-can-facebook-and-its-users-burst-the-filter-bubble/ How reporting via social networks leads to bias & how to "flip the feed"
Posts Tagged ‘networks’
Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease: CellOctober 1, 2016
Zhang, Bin, Chris Gaiteri, Liviu-Gabriel Bodea, Zhi Wang, Joshua McElwee, Alexei A. Podtelezhnikov, Chunsheng Zhang et al. "Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease." Cell 153, no. 3 (2013): 707-720.
Integrated systems approach identifies genetic…#networks in…Alzheimer’s http://www.Cell.com/cell/abstract/S0092-8674(13)00387-5 Determining causality from co-expression
Evolutionary Origins of Hierarchy
http://journals.plos.org/ploscompbiol/article?id=10.1371%2Fjournal.pcbi.1004829 Simulations explain how connection cost drives formation in sparse #networks
All Your Friends Have More Friends Than You
http://nymag.com/scienceofus/2016/05/turns-out-all-your-friends-have-more-friends-than-you.html Twist on social #networks having a #powerlaw degree distribution
The paradox arises because numbers of friends people have are distributed in a way that follows a power law rather than an ordinary linear relationship. So most people have a few friends while a small number of people have lots of friends.
DREM 2.0: Improved reconstruction of dynamic regulatory networks from time-series expression data | BMC Systems Biology | Full TextApril 8, 2016
DREM…reconstruction of…regulatory #networks from time-series expression http://bmcsystbiol.biomedcentral.com/articles/10.1186/1752-0509-6-104 Classic approach using 3-level IO #HMMs
Understanding multicellular function and disease with human tissue-specific networks : Nature Genetics : Nature Publishing GroupNovember 28, 2015
Human tissue-specific #networks by @TroyanskayaLab
Brain-specific ones & NetWAS approach for combining #GWAS genes
access all tissue networks including the brain-specific
networks at giant.princeton.edu
LinkedIn’s Plan for World Domination http://www.newyorker.com/magazine/2015/10/12/the-network-man No job security, everyone’s an entrepreneur, enlarging prof’l #networks is key
“Manyika understood that not every chief executive in Silicon Valley could sign the statement, but he was gently trying to pull Hoffman to the left, and he knew how to frame the argument so that it would appeal to him. He went on, “We cannot ignore this problem. Right now, everybody’s punting. We know the share of income that goes to wages is a declining portion, compared with capital expenditures. What does that mean for jobs? Entrepreneurship is part of the answer. Mass-scale entrepreneurship. Before you even get to A.I.”
“You have to be able to let people adapt,” Hoffman said. “You have to have cheap resources to put across the whole system. How do you get inclusion within the tech ecosystem?”
“Very few of the programs have scale,” Manyika said.
“You have to scale to infinite,” Hoffman said.
Modern Lessons from [reconstructing] Ancient Food Webs http://www.americanscientist.org/issues/feature/2015/3/modern-lessons-from-ancient-food-webs/1 Overall #network structure (eg degree dist.) fairly invariant
$BMY rips up its R&D group…800-plus [affected]
http://www.fiercebiotech.com/story/bristol-myers-rips-its-rd-group-adding-eliminating-and-moving-hundreds/2015-06-25 Trend of pruning spoke cities & growing #hub ones HT @JorgensenWL
“Bristol-Myers Squibb’s big reorganization fits into the industry’s new model for R&D. Large, scattered groups are out as big
organizations gravitate toward the big hubs. GlaxoSmithKline ($GSK) and Amgen ($AMGN) have offered two recent examples of that trend, which has benefited hubs like Boston/Cambridge and the Bay Area while inflicting painful cuts in outlying areas. Biopharma companies are also concentrating on core areas, sometime shedding early-stage work–reflected in Merck’s ($MRK) recent downsizing at the newly acquired Cubist and the big asset swap that occurred between GlaxoSmithKline and Novartis ($NVS).”